


APPLICATION**An Oxidation Process for the Preparation of N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-{N-[(tert-butylamino)carbonyl]-3-methyl-L-valyl}-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide and Related Compounds****Field of the Invention**

This invention relates to a novel oxidation process for the preparation of N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-{N-[(tert-butylamino)carbonyl]-3-methyl-L-valyl}-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide compounds having the following structure of formula A:



and other related compounds, including all stereoisomers.

Background of the Invention

(1R,2S,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-{N-[(tert-butylamino)carbonyl]-3-methyl-L-valyl}-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide is disclosed in U.S. Publication No. 2003/0126324 A1 and copending US applications Ser. Nos. 10/052,386, which was filed January 18, 2002, 10/867,600, 10/867,601, and 10/867,602 which were all filed on June 15, 2004, all of which are each incorporated herein by reference.

The compound of formula A is a hepatitis C virus ("HCV") protease inhibitor, useful for treating hepatitis C and related disorders. Specifically, the compound of formula A is an inhibitor of the HCV NS3/NS4a serine protease.


There remains a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of hepatitis C.

In view of the importance of hepatitis C virus ("HCV") protease inhibitors, new, novel methods of making such antagonists are always of interest.

5

Summary of the Invention

In an aspect, the present application relates to process of making a compound of formula I:



10 wherein


R¹ is alkyl;

R² is alkyl; and

R³ is optionally substituted cycloalkylalkyl

including all stereoisomers, rotomers, enantiomers and diastereomers

15 by oxidizing a compound of formula II



The inventive oxidation process to make compounds of formula I has several advantages, including the provision of a simple one step oxidation procedure to form the compound of formula I in high yield.

20

Description of the Invention

As used above, and throughout the specification, the following terms, unless
5 otherwise indicated, shall be understood to have the following meanings:

"Alkyl" means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain. More preferred
10 alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain. "Lower alkyl" means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched. The term "substituted alkyl" means that the alkyl group may be substituted by one or more substituents which may
15 be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, -NH(alkyl), -NH(cycloalkyl), -N(alkyl)₂, carboxy and -C(O)O-alkyl. Non-limiting examples of suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, heptyl, nonyl, decyl, fluoromethyl, trifluoromethyl and
20 cyclopropylmethyl.

"Alkenyl" means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have about 2 to about
25 12 carbon atoms in the chain; and more preferably about 2 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkenyl chain. "Lower alkenyl" means about 2 to about 6 carbon atoms in the chain which may be straight or branched. The term "substituted alkenyl" means that the alkenyl group may be substituted by one or more
30 substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, and alkoxy. Non-limiting examples of suitable alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl, octenyl and decenyl.

"Aryl" means an aromatic monocyclic or multicyclic ring system comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms. The aryl group can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein. Non-limiting examples of suitable aryl groups include phenyl and naphthyl.

"Heteroaryl" means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example, nitrogen, oxygen or sulfur, alone or in combination. Preferred heteroaryls contain about 5 to about 6 ring atoms. The "heteroaryl" can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein. The prefix aza, oxa or thia before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom. A nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide. Non-limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxaliny, phthalazinyl, imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinoliny, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinoliny, benzoazaindolyl, 1,2,4-triazinyl, benzothiazolyl and the like.

"Aralkyl" means an aryl-alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.

"Alkylaryl" means an alkyl-aryl- group in which the alkyl and aryl are as previously described. Preferred alkylaryls comprise a lower alkyl group. Non-limiting examples of suitable alkylaryl groups include o-tolyl, p-tolyl and xylyl. The bond to the parent moiety is through the aryl.

5

"Cycloalkyl" means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms. Preferred cycloalkyl rings contain about 5 to about 7 ring atoms. The cycloalkyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above. Non-limiting examples of suitable monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalin, norbornyl, adamantyl and the like.

10 "Halo" means fluoro, chloro, bromo, or iodo groups. Preferred are fluoro, chloro or bromo, and more preferred are fluoro and chloro.

"Halogen" means fluorine, chlorine, bromine, or iodine. Preferred are fluorine, chlorine or bromine, and more preferred are fluorine and chlorine.

15 "Ring system substituent" means a substituent attached to an aromatic or non-aromatic ring system which, for example, replaces an available hydrogen on the ring system. Ring system substituents may be the same or different, each being independently selected from the group consisting of aryl, heteroaryl, aralkyl, alkylaryl, aralkenyl, heteroaralkyl, alkylheteroaryl, heteroaralkenyl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, Y₁Y₂N-, Y₁Y₂N-alkyl-, Y₁Y₂NC(O)- and Y₁Y₂NSO₂-, wherein Y₁ and Y₂ may be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryl, and aralkyl.

30 "Cycloalkenyl" means a non-aromatic mono or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms which contains at least one carbon-carbon double bond. Preferred cycloalkenyl rings contain about 5 to about 7 ring atoms. The cycloalkenyl can be optionally substituted with one or more "ring system substituents" which may be the same or

different, and are as defined above. Non-limiting examples of suitable monocyclic cycloalkenyls include cyclopentenyl, cyclohexenyl, cycloheptenyl, and the like. Non-limiting example of a suitable multicyclic cycloalkenyl is norbornenyl.

5 "Cycloalkylalkyl" means a cycloalkyl-alkyl group in which the cycloalkyl and alkyl groups are as previously described. The cycloalkyl portion may be optionally substituted with one or more "ring system substituents." The alkyl portion may be substituted with one or more alkyl substituents as defined above.

10 "Heterocyclenyl" means a non-aromatic monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur atom, alone or in combination, and which contains at least one carbon-carbon double bond or carbon-nitrogen double bond.

15 There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclenyl rings contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclenyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. The heterocyclenyl can be optionally substituted by one or more ring system substituents, wherein "ring system

20 substituent" is as defined above. The nitrogen or sulfur atom of the heterocyclenyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable monocyclic azaheterocyclenyl groups include 1,2,3,4-tetrahydropyridine, 1,2-dihydropyridyl, 1,4-dihydropyridyl, 1,2,3,6-tetrahydropyridine, 1,4,5,6-tetrahydropyrimidine, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolyl, 2-pyrazolyl,

25 and the like. Non-limiting examples of suitable oxaheterocyclenyl groups include 3,4-dihydro-2H-pyran, dihydrofuranyl, fluorodihydrofuranyl, and the like. Non-limiting example of a suitable multicyclic oxaheterocyclenyl group is 7-oxabicyclo[2.2.1]heptenyl. Non-limiting examples of suitable monocyclic thiaheterocyclenyl rings include dihydrothiophenyl, dihydrothiopyranyl, and the like.

30

"Heterocyclyl" means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than

carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclyls contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom
5 respectively is present as a ring atom. The heterocyclyl can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein. The nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl,
10 morpholinyl, thiomorpholinyl, thiazolidinyl, 1,3-dioxolanyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, and the like.

"Aralkenyl" means an aryl-alkenyl- group in which the aryl and alkenyl are as previously described. Preferred aralkenyls contain a lower alkenyl group. Non-limiting
15 examples of suitable aralkenyl groups include 2-phenethenyl and 2-naphthylethenyl. The bond to the parent moiety is through the alkenyl.

"Heteroaralkyl" means a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as previously described. Preferred heteroaralkyls contain a lower alkyl group.
20 Non-limiting examples of suitable aralkyl groups include pyridylmethyl, 2-(furan-3-yl)ethyl and quinolin-3-ylmethyl. The bond to the parent moiety is through the alkyl.

"Heteroaralkenyl" means an heteroaryl-alkenyl- group in which the heteroaryl and alkenyl are as previously described. Preferred heteroaralkenyls contain a lower
25 alkenyl group. Non-limiting examples of suitable heteroaralkenyl groups include 2-(pyrid-3-yl)ethenyl and 2-(quinolin-3-yl)ethenyl. The bond to the parent moiety is through the alkenyl.

"Hydroxyalkyl" means a HO-alkyl- group in which alkyl is as previously defined.
30 Preferred hydroxyalkyls contain lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.

"Acyl" means R-C(O)- group wherein R is, for example, hydrogen or any of the groups described in the definitions listed above. Examples of such groups include H-C(O)-, alkyl-C(O)-, alkenyl-C(O)-, alkynyl-C(O)-, cycloalkyl-C(O)-, cycloalkenyl-C(O)-, or cycloalkynyl-C(O)- group. The bond to the parent moiety is through the carbonyl.

5 Preferred acyls contain a lower alkyl. Non-limiting examples of suitable acyl groups include formyl, acetyl, propanoyl, 2-methylpropanoyl, butanoyl and cyclohexanoyl.

"Aroyl" means an aryl-C(O)- group in which the aryl group is as previously described. The bond to the parent moiety is through the carbonyl. Non-limiting
10 examples of suitable groups include benzoyl and 1- and 2-naphthoyl.

"Alkoxy" means an alkyl-O- group in which the alkyl group is as previously described. Non-limiting examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy and heptoxy. The bond to the parent moiety is
15 through the ether oxygen.

"Aryloxy" means an aryl-O- group in which the aryl group is as previously described. Non-limiting examples of suitable aryloxy groups include phenoxy and naphthoxy. The bond to the parent moiety is through the ether oxygen.
20

"Aralkyloxy" means an aralkyl-O- group in which the aralkyl groups is as previously described. Non-limiting examples of suitable aralkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy. The bond to the parent moiety is through the ether oxygen.
25

"Alkylamino" means an -NH₂ or -NH₃⁺ group in which one or more of the hydrogen atoms on the nitrogen is replaced by an alkyl group as defined above.

"Arylamino" means an -NH₂ or -NH₃⁺ group in which one or more of the
30 hydrogen atoms on the nitrogen is replaced by an aryl group as defined above.

"Alkylthio" means an alkyl-S- group in which the alkyl group is as previously described. Non-limiting examples of suitable alkylthio groups include methylthio,

ethylthio, i-propylthio and heptylthio. The bond to the parent moiety is through the sulfur.

"Arylthio" means an aryl-S- group in which the aryl group is as previously
5 described. Non-limiting examples of suitable arylthio groups include phenylthio and naphthylthio. The bond to the parent moiety is through the sulfur.

"Aralkylthio" means an aralkyl-S- group in which the aralkyl group is as
previously described. Non-limiting example of a suitable aralkylthio group is
10 benzylthio. The bond to the parent moiety is through the sulfur.

"Alkoxycarbonyl" means an alkyl-O-CO- group. Non-limiting examples of
suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl. The
bond to the parent moiety is through the carbonyl.

15

"Aryloxycarbonyl" means an aryl-O-C(O)- group. Non-limiting examples of
suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl. The
bond to the parent moiety is through the carbonyl.

20

"Aralkoxycarbonyl" means an aralkyl-O-C(O)- group. Non-limiting example of a
suitable aralkoxycarbonyl group is benzyloxycarbonyl. The bond to the parent moiety
is through the carbonyl.

25

"Alkylsulfonyl" means an alkyl-S(O₂)- group. Preferred groups are those in
which the alkyl group is lower alkyl. The bond to the parent moiety is through the
sulfonyl.

30

"Alkylsulfinyl" means an alkyl-S(O)- group. Preferred groups are those in which
the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfinyl.

"Arylsulfonyl" means an aryl-S(O₂)- group. The bond to the parent moiety is
through the sulfonyl.


10

"Arylsulfinyl" means an aryl-S(O)- group. The bond to the parent moiety is through the sulfinyl.


The term "optionally substituted" means optional substitution with the specified
5 groups, radicals or moieties.

The disclosure provides methods for preparing compounds of formula I,
including various isomers and pharmaceutically acceptable salts. It will be
appreciated that the present description can be modified to provide variously desired
10 isomers and salts, which are within the scope of the invention.

One embodiment of the invention involves a process of making a compound of
formula **IA** comprising:



15 wherein R^1 , R^2 and R^3 are defined above
which comprises oxidizing a compound of formula **IIA**




to yield a compound of formula **IA**.

20


11

Another embodiment of the invention is a process of making a compound of formula **IB**




wherein R^1 , R^2 and R^3 are defined above,

5 which comprises oxidizing a compound of formula **IIB**



to yield a compound of formula **IB**.


10 Another embodiment of the invention is a process for making a compound of formula **IC**



wherein R^1 , R^2 and R^3 are defined above


which comprises oxidizing a compound of formula **IIC**

15




to yield a compound of formula **IC**.

- 5 Another embodiment of the invention is a process of making a compound of formula **ID**,



wherein R^1 , R^2 and R^3 are defined above
which comprises oxidizing a compound of formula **IID**

10



to yield a compound of formula **ID**.

- 15 Compounds of formula **II** can be prepared according to processes found in the prior art, for example, those found in US Publication Nos. US 2003/0216325 A1 and US 2004/0254117 A9, both herein incorporated by reference. It will be appreciated that the processes disclosed therein can be modified without undue experimentation to prepare specifically desired starting materials.

Non-limiting examples of an oxidation agent that oxidizes compounds of formula II to those of formula I include Na(ClO), Ca(OCl)₂, and NaBrO₃. The oxidation agent can be used generally in an amount ranging from about 0 to 4, and for example from about 1 to about 2 equivalents with respect to a compound of formula II.

5

In some embodiments of the invention, it is preferred for the process to include the use of a catalyst and optionally a co-catalyst. Non-limiting examples of a catalyst that may be used in the inventive process include tetramethylpiperidinyloxy (TEMPO), 2-methoxyTEMPO, and 4-aminoTEMPO. The catalyst can be used generally in an amount ranging from about 0.1 to about 3, and for example from about 1 to about 2 equivalents with respect to a compound of formula II.

10

In some embodiments of the invention, it is preferred to have at least one co-catalyst is present in the reaction mixture. Non-limiting examples of suitable co-catalysts include metal acetates, for example, sodium, lithium or potassium acetate, metal halides, for example, sodium bromide, potassium bromide or sodium iodide. The co-catalyst can be used in amounts ranging from 0 to saturation, more preferably from 0 to about 2 equivalents or from about 0.5 to about 1.5 equivalents and most preferably about 0.9 equivalents, all with respect to a compound of formula II. When present, preferably 1 or 2 co-catalysts are present in the process.

15

20

Another embodiment of the inventive process includes the presence of an acid. Non-limiting examples of acids include acetic acid or a halogenated acetic acid, such as ClCH₂COOH, Cl₂CHCOOH, Cl₃CCOOH, and CF₃COOH. The acid can be used generally in an amount ranging from about 0.1 to about 3, and for example from about 1 to about 2 equivalents with respect to a compound of formula II.

25

Non-limiting examples of solvents include esters, ethers, water or mixtures thereof. A biphasic solvent system can be used, for example a system comprising t-butyl methylether and water. Preferably the solvent is methyl tertiary-butyl ether (MTBE).

30

The oxidation can be carried out at a temperature ranging from about 0°C to about 80°C, for example from about 10°C to about 50°C, and as a further example from about 15°C to about 30°C.

5 In some embodiments of the present invention, it is preferred to carry out the oxidation by contacting a compound selected from a compound of Formula **IIA**, **IIB**, **IIC** and **IID** with an oxidation agent, a catalyst, one or two co-catalysts, and an acid in a solvent or solvent mixture.

10 In some embodiments of the present invention process employing a catalyst, it is preferred to include additionally, after the oxidation step, a step in which the catalyst is removed by adding to the reaction mixture a catalyst removing reagent. Examples of catalyst removing reagents include, but are not limited to, ascorbic acid and one or more of a mineral acid, for example, HCl and HBr, and mixtures of two or more
15 thereof. The catalyst removing reagent can generally be used in an amount ranging from 0 to about 4 equivalents, more preferably from about 0.1 to about 3 equivalent or from about 1 to about 3 equivalents.

In some embodiments employing a mineral acid as a catalyst removing
20 reagent, it is preferred to use a mineral acid concentration of from about 1N to about 5N. In some embodiments using HCl as a catalyst removing reagent it is preferred to use a concentration of HCl which is about 3.5 N. In some embodiments using a mineral acid as a catalyst removing reagent it is preferred to use the mineral acid in an amount of from about 1 to about 10 times the amount of catalyst employed.

25 Preferred groups for R^1 and R^2 include methyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl, iso-butyl or tert-butyl. Especially preferred are compounds wherein R^1 and R^2 are both tert-butyl.

30 Preferred groups for R^4 include groups of the formula $-(CH_2)_n-R^4$, wherein R^4 is a moiety selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl and n is an integer from 1-10, more preferably from 1-5. Especially preferred compounds are those wherein n is 1 and R^4 is cyclobutyl.


Representative illustrative procedures are outlined in the following reaction schemes. It is to be understood that while the following illustrative schemes describe the preparation of a few representative inventive compounds, suitable substitution can result in the formation of the desired compounds based on such substitution. Such variations are contemplated to be within the scope of the invention.

The following non-limiting EXAMPLE is provided in order to further illustrate the present invention. It will be apparent to those skilled in the art that many modifications, variations and alterations to the present disclosure, both to materials, methods and reaction conditions, can be practiced. All such modifications, variations and alterations are intended to be within the spirit and scope of the present invention.

EXAMPLES

Preparation of (1R,2S,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-{N-[(tert-butylamino)carbonyl]-3-methyl-L-valyl}-6,6-dimethyl-3-azabicyclo-[3.1.0]hexane-2-carboxamide (the compound of Structure 2 in Scheme A, below)

Scheme A



Unless otherwise stated, the following abbreviations have the stated meanings in the Examples below:

g = grams

mL = milliliters

eq = equivalents

mmols = millimols

DMF = dimethylformamide

NaOAc = sodium acetate

5 TEMPO = 2,2,6,6-tetramethyl-1-piperidinyloxy free radical (available from Aldrich and used as received)

MTBE = methyl tert-butyl ether

NaOCl = sodium hypochlorite

Equiv = equivalent(s)

10

Unless otherwise noted all solvents are articles of commerce and all reagents were used as received.

15

Example 1: Preparation of Compound 2 using aqueous acetic acid in the reaction mixture

Into a 1L, three necked flask is placed KBr (10 g, 84 mmol), NaOAc (10 g, 122 mmol), Compound 1 (50 g, 96 mmol), and TEMPO (15 g, 96 mmol), followed by 500 mL of MTBE. The reaction mixture is stirred at 350-400 rpm and the temperature is maintained at a temperature of from 10°C to 20°C. Acetic acid (50 mL, 874 mmol), and water (5 mL) are added to the reaction mixture and the two phase mixture is agitated for 15 minutes. Continuously, over a two hour period, to the reaction mixture is added 158 mL of a 0.82 M solution of NaOCl (130 mmol). When all of the NaOCl solution is added, the reaction mixture is stirred for an additional 3 hours while maintaining the temperature. Water (50 mL) is added. The layers are separated and the organic layer is washed twice with water (2 x 250 mL). A solution of ascorbic acid, which is prepared from 50 g of sodium ascorbate, 200 mL of water, and 50 mL of 4N HCl, is added to the organic layer and the mixture is stirred for about 1 hour. After the layers are separated, the organic layer is washed twice with water (2 x 250 mL). The organic layer is concentrated by distilling off solvent at low temperature (0-5°C) until the total volume is about 350 mL. The concentrated organic layer is added dropwise over 30 minutes into a 3L flask containing 2L of n-heptane at about 0°C providing a white precipitate. The white precipitate is collected by filtration, washed with n-

heptane (400 mL) and dried in a vacuum oven (2 hr at 25°C, 8 hr at 35°, and 8°C at 45°C). The product is obtained as a white powder (typically 94-96% yield). ¹H NMR, δ 0.84 (d, *J* = 2.3 Hz, 3H), 0.90-1.02 (m, 9H), 0.99 (d, *J* = 4.0 Hz, 3H), 1.24 (s, 9H), 1.40-1.86 (m, 7H), 1.90-2.10 (m, 3H), 2.25-2.40 (m, 1H), 3.75 (dd, *J* = 5.3 and 10.4 Hz, 1H), 4.10 (dd, *J* = 6.8 and 10.4 Hz, 1H), 4.4 (dd, *J* = 3.0 and 5.3 Hz, 2H), 5.17 (dddd, *J* = 4.6, 8.1, 8.1, and 10.4 Hz, 1H), 5.3 (br s, 2H), 6.71 (d, *J* = 14.7 Hz, 1H), 6.90 (dd, *J* = 2.3 and 19.0 Hz, 1H), and 7.34 (dd, *J* = 7.1 and 20.2 Hz, 1H).

Example 2: Preparation of Compound 2 using glacial acetic acid in the reaction mixture

Into a 2L, three necked flask was charged KBr (20 g, 168 mmol), NaOAc (20 g, 243 mmol), Compound 1 (100 g, 192 mmol), and TEMPO (30 g, 192 mmol), followed by 800 mL of MTBE. The reaction mixture was stirred at 350-400 rpm while the temperature of the reaction mixture was maintained at a temperature of from 10°C to 20 °C. Acetic acid (70 mL, 1223 mmol, used as received), was added and the mixture was agitated for 15 minutes additional. Continuously, over a two hour period, 315 ml of a 0.73M solution of NaOCl (230 mmol) was added to the reaction mixture. When all of the NaOCl solution had been added, agitation was continued for an additional 3 hours. Water (100 mL) was added to the reaction mixture at the end of 3 hours. The layers were separated and the organic layer was washed once with water (500 mL). A solution of ascorbic acid, which was prepared from 100 g of sodium ascorbate, 456 mL of water, and 44 mL of 36% HCl, was added to the organic layer and the mixture was stirred for about 2 hours. The layers were separated and then a solution of 3.5N HCL was added and stirred about 30 minutes. After the layers were separated, the organic layer was washed three times with water (3 x 500 mL). This organic layer was then added drop-wise over 30 minutes into a 5L flask containing 3L of n-heptane at about -10 to about 0 °C. The white precipitate was filtered, washed with n-heptane (600 mL) and dried in a vacuum oven (2 hr at 25°C, 8 hr at 35°, and 8°C at 45°C). The product was obtained as a white powder (93% yield). ¹H NMR, δ 0.84 (d, *J* = 2.3 Hz, 3H), 0.90-1.02 (m, 9H), 0.99 (d, *J* = 4.0 Hz, 3H), 1.24 (s, 9H), 1.40-1.86 (m, 7H), 1.90-2.10 (m, 3H), 2.25-2.40 (m, 1H), 3.75 (dd, *J* = 5.3 and 10.4 Hz, 1H), 4.10 (dd, *J* = 6.8 and 10.4 Hz, 1H), 4.4 (dd, *J* = 3.0 and 5.3 Hz, 2H), 5.17 (dddd, *J* = 4.6, 8.1, 8.1, and

10.4 Hz, 1H), 5.3 (br s, 2H), 6.71 (d, $J = 14.7$ Hz, 1H), 6.90 (dd, $J = 2.3$ and 19.0 Hz, 1H), and 7.34 (dd, $J = 7.1$ and 20.2 Hz, 1H).

It will be understood that various modifications can be made to the
5 embodiments and examples disclosed herein. Therefore, the above description
should not be construed as limiting, but merely as exemplifications of preferred
embodiments. Those skilled in the art will envision various modifications within the
scope and spirit of the claims appended hereto.

What is claimed is:

1. A process for resolving the S-isomer of 2-piperidin-2-yl ethanol from a mixture of isomers, the process comprising: (a) combining a solution comprising a polar, aprotic organic solvent and a mixture of isomers of 2-piperidin-2-yl-ethanol with an aliphatic alcohol solution containing an amino acid resolving agent selected from N-acetyl-L-leucine and N-acetyl-L-methionine; (b) mixing the combined solutions with additional amounts of the polar, aprotic organic solvent used in Step "a" and warming the mixture to a temperature below the boiling point of either solvent in the mixture sufficient to promote dissolution of any solids present in the mixture; (c) cooling the mixture to a temperature which permits salt precipitation therefrom; (d) isolating the precipitated salt formed in step "c"; and (e) purifying the isolated salt from Step "d" by recrystallization or slurrying with a purifying solvent, and optionally repeating the recrystallization or slurrying step until the desired enantiomeric purity is achieved.
2. The process of claim 1 wherein the polar aprotic organic solvent used in said "combining" Step "a" is a solvent selected from tetrahydrofuran (THF), acetonitrile (ACN), acetone, and ethylacetate, and mixtures of two or more thereof.
3. The process of claim 1 wherein, wherein the aliphatic alcohol used in Step "a" is an alcohol having 5 carbon atoms or less.
4. The process of claim 2 wherein said polar aprotic organic solvent (PAO solvent) in step "a" is THF and the alcohol in step "a" is methanol.
5. The process of claim 1 wherein, said recrystallization step "e", when carried out, is carried out in a mixed solvent.
6. The process of claim 2 wherein, said recrystallization step "e", when carried out, is carried out in a mixed solvent.
7. The process of claim 3 wherein, said recrystallization step "e", when carried out, is carried out in a mixed solvent.
8. The process of claim 5 wherein, when carried out, said mixed solvent used in Step "e" is a mixture of a solvent selected from acetonitrile and THF and an aliphatic alcohol having 5 or fewer carbon atoms.
9. The process of claim 6 wherein, when carried out, said mixed solvent used in Step "e" is a mixture of a solvent selected from acetonitrile and THF and an aliphatic alcohol having 5 or fewer carbon atoms.
10. The process of claim 7 wherein, when carried out, said mixed solvent used in Step "e" is a mixture of a solvent selected from acetonitrile and THF and an aliphatic alcohol having 5 or fewer carbon atoms.


11. The process of claim 2 wherein, said Step "e" is carried out in a mixture comprising 19 volumes of acetonitrile and 1 volume of methanol.
12. The process of claim 3 wherein, said Step "e" is carried out in a mixture comprising 19 volumes of acetonitrile and 1 volume of methanol.
13. The process of claim 1 further comprising the steps of: (i) providing a mixture comprising redissolving or suspending a precipitated salt obtained from optional step "d" or step "e" in a solvent; and (ii) treating the mixture from step "i" with a base to yield (S)2-piperidine-2-yl-ethanol free base.
14. The process of claim 1 further including obtaining a precipitated salt from optional step "d" or optional step "e", and is introducing it into a reaction mixture containing a base, thereby providing (S)2-piperidine-2-yl-ethanol free base in situ in the reaction mixture.
15. The process of claim 1 wherein, the resolving agent in step "a" is N-acetyl-L-leucine.
16. The process of claim 9 wherein, the resolving agent in step "a" is N-acetyl-L-leucine.
17. The process of claim 16 wherein, the resolving agent is present in the step "a" solution in an amount sufficient to provide a solution of about 5 M in resolving agent.
18. The process of claim 1 wherein, the mixture of solvents used in Step "a", the combining step, comprises a volumetric ratio of polar aprotic organic solvent (PAO solvent):aliphatic alcohol of from about 2:1 PAO solvent:aliphatic alcohol to about 10:1 PAO solvent:aliphatic alcohol.
19. The process of claim 18 wherein the mixture of solvents used in Step "a" comprises a volumetric ratio of about 5:1 PAO solvent:aliphatic alcohol.
20. The process of claim 3 wherein the THF solution used in Step "a" comprises at least an amount of 2-piperidin-2-yl-ethanol sufficient to provide a 2M solution.
21. The process of claim 1 wherein the combined methanol and THF solutions in step "a" are maintained at a temperature of from about 20 °C. to about 60 °C.
22. The process of claim 21 wherein the combined methanol and THF solutions in step "a" are maintained at a temperature of from about 35 °C. to about 40 °C.
23. The process of claim 1 wherein the solution of step "b" is heated to a temperature of from about 30 °C. to a temperature below the refluxing temperature of the solvent mixture.
24. The process of claim 23 wherein the solution of step "b" is heated to a temperature of

from about 50 °C. to about 55 °C.

25. The process of claim 1 wherein said purification step "e" is carried out by heating the precipitate formed in step "d" in a mixture of 1 vol. eq. of methanol and 20 vol. eq. of acetonitrile to a temperature of about 55 °C and cooling it to a temperature of about 15 °C.

26. The process of claim 1 wherein said purification step "e" is carried out by heating a slurry comprising a mixture of 1 vol. eq. of methanol, 20 vol. eq. of acetonitrile, and the precipitate formed in step "d" to a temperature of about 55 °C., holding the slurry at temperature for a time sufficient to dissolve the impurities, and cooling the slurry to a temperature of about 15 °C.

27. A process for making pyrazolo[1,5-a]pyrimidin-7-yl-amino compounds of Formula III




Formula III

wherein R² is a linear, branched or cyclic alkyl group, the process comprising:


- (a) combining a solution comprising a polar, aprotic organic solvent and a mixture of isomers of 2-piperidin-2-yl-ethanol with an aliphatic alcohol solution containing an amino acid resolving agent selected from N-acetyl-L-leucine and N-acetyl-L-methionine;
- (b) mixing the combined solutions with additional amounts of the polar, aprotic organic solvent and warming the mixture to a temperature below the boiling point of either solvent in the mixture sufficient to promote dissolution of any solids present in the mixture;
- (c) cooling the mixture to a temperature which permits the salt of compound G1a to precipitate therefrom,

G1a



- (d) isolating the precipitated salt formed in step "c",
 (e) purifying the salt from step "c" by slurrying the salt in a 10:1 by volume mixture of acetonitrile (ACN) and methanol;
 (f) liberating the free base alcohol G1a from the salt prepared in purifying Step "e"; and
 (g) reacting the free base alcohol from Step "e" with the compound of Formula G1,

G1



wherein "X" is a halogen or sulfonyl leaving group.

28. The process of claim 27 wherein, "R²" is an ethyl-substituent and X is C¹.

29. The process of claim 27 wherein, the polar, aprotic organic solvent in Step "a" is selected from tetrahydrofuran (THF), acetonitrile (ACN), ethyl acetate and acetone.

30. The process of claim 29 wherein, the aliphatic alcohol in Step "a" is selected from aliphatic alcohols having 5 carbon atoms or less.
31. The process of claim 29 wherein, the aliphatic alcohol in Step "a" is methanol.
32. The process of claim 27 wherein, said liberating step "e" is carried out by combining the isolated resolved salt with a reaction mixture in the presence of a base and liberating the free base alcohol in situ.
33. The process of claim 27 wherein, said liberating step "e" is carried out by treating the isolated resolved salt with a base, crystallizing the free base alcohol out of solution, and isolating the free base crystals by filtration.
34. A process for resolving the S-isomer of 2-piperidin-2-yl ethanol from a mixture of isomers, the process comprising: (a) combining a tetrahydrofuran (THF) solution containing a mixture of isomers of 2-piperidin-2-yl ethanol with a methanol solution containing N-acetyl-L-leucine; (b) mixing the combined solutions with additional THF and warming the mixture to a temperature below the boiling point of either solvent in the mixture; (c) cooling the mixture to a temperature which permits salt precipitation therefrom; (d) isolating the precipitated salt formed in step "c"; and (e) optionally recrystallizing the salt.
35. The process of claim 34 further comprising the steps of: (i) dissolving or suspending a precipitated salt obtained from optional step "d" or optional step "e" in a solvent; and (ii) treating the mixture from step "i" with a base to yield (S)-2-piperidine-2-yl-ethanol free base.
36. The process of claim 35 wherein said solvent used in Step "i" is a sodium hydroxide aqueous solution, thereby providing the solvent and base treatment in a single step.
37. The process of claim 27 wherein, the mixture of solvents used in Step "a", the combining step, comprises a volumetric ratio of polar aprotic organic solvent (PAO solvent):aliphatic alcohol of from about 2:1 PAO solvent:aliphatic alcohol to about 10:1 PAO solvent:aliphatic alcohol.
38. The process of claim 37 wherein, the resolving agent is present in the step "a" solution in an amount sufficient to provide a solution of about 5 M in resolving agent.
39. The process of claim 27 wherein said purification step "e" is carried out by heating the precipitate formed in step "d" to a temperature of about 55 °C. and cooling it to a temperature of about 15 °C.